Adial Pharmaceuticals has appointed David Rubenstein, M.D., Ph.D., as Chief Scientist, where he will lead the Glen Allen, Virginia-based company’s research and scientific strategy. Rubenstein will oversee the development of AT177, an investigational oral therapy for ulcerative colitis, including studies supporting a planned transition into human clinical trials in 2027.
About David Rubenstein
Rubenstein brings extensive experience in drug development and aryl hydrocarbon receptor (AhR) biology. He previously served as Chief Scientific Officer at Dermavant Sciences, where he led the development, regulatory approval, and commercialization of tapinarof (VTAMA), the first FDA-approved AhR agonist, for plaque psoriasis and atopic dermatitis.
Earlier in his career, Rubenstein held senior roles focused on preclinical drug development at Stiefel and GSK. He earned both his M.D. and Ph.D. from Duke University.
At Adial, Rubenstein will oversee discovery, translational, and nonclinical research, including studies evaluating AT177’s mechanism of action and its ability to target the colon while limiting systemic exposure.
About Adial Pharmaceuticals
Adial Pharmaceuticals is a biopharmaceutical company based in Glen Allen, Virginia, focused on developing treatments for serious inflammatory diseases. Following its acquisition of Azora Therapeutics in June 2026, the company’s lead program is AT177, an oral, colon-targeted AhR agonist being developed for ulcerative colitis. The program is currently undergoing IND-enabling studies, with clinical trials planned for 2027.
